New drug combo aims to shrink prostate tumors before surgery
NCT ID NCT00329043
First seen Nov 10, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study looks at whether adding sunitinib to hormone therapy can shrink or control high-risk prostate cancer before surgery to remove the prostate. About 64 participants will receive the combination treatment, then have their prostate removed to check for complete tumor disappearance. The goal is to improve outcomes for patients with aggressive localized prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.